💼 My Portfolio 👁 Watchlist 🧠 AI Stock Analysis 🤖 AI Portfolio Analysis 📊 Fear & Greed 💬 Community 🔴 Live 📰 Archives 🛒 Shop

← Back to Screener

Lumibird

LBIRD.PA Small Cap

Healthcare · Diagnostics & Research

Updated: May 22, 2026, 22:06 UTC

€24.85
+1.84% today
52W: €13.00 – €26.10
52W Low: €13.00 Position: 90.5% 52W High: €26.10

Key Metrics

P/E Ratio
38.83x
Price-to-Earnings
Forward P/E
21.24x
Forward Price/Earnings
P/S Ratio
2.4x
Price-to-Sales
EV/EBITDA
19.2x
Enterprise Value/EBITDA
Div. Yield
1.49%
Annual dividend yield
Market Cap
$548.3M
Market Capitalization
Revenue Growth
8.5%
YoY Revenue Growth
Profit Margin
6.13%
Net profit margin
ROE
6.93%
Return on Equity
Beta
0.87
Market sensitivity
Short Interest
—
% of float sold short
Avg. Volume
38,913
Average daily volume

Valuation Analysis

Signal
Overvalued
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Strong Buy
3 analysts
Avg. Price Target
€29.50
+18.71% upside
Target Range
€28.50 – €30.00

About the Company

Lumibird SA designs, manufactures, and sells various lasers for scientific, industrial, and medical applications in France, Hong Kong, the United States, Germany, South Korea, China, and Austria. The company operates through Photonics and Medical divisions. It offers fiber lasers and amplifiers, high power fiber lasers, and solid-state lasers, laser diodes and components; and doppler wind LiDAR, time-of-flight LiDAR and rangefinders, military laser rangefinders, and medical and ophthalmological solutions. The company serves defense and space, environment, topography and safety, industry and science, and science and healthcare industries. Lumibird SA was incorporated in 1970 and is headquartered in Lannion, France. Lumibird SA is a subsidiary of ESIRA.

Sector: Healthcare Industry: Diagnostics & Research Country: France Employees: 1,078 Exchange: PAR

Lumibird Stock at a Glance

Lumibird (LBIRD.PA) is currently trading at €24.85 with a market capitalization of $548.3M. The trailing P/E ratio stands at 38.83x, with a forward P/E of 21.24x. The 52-week range spans from €13.00 to €26.10; the current price is 4.8% below the yearly high. Year-over-year revenue growth stands at +8.5%. The net profit margin stands at 6.13%.

💰 Dividend

Lumibird pays an annual dividend of €0.37 per share, representing a yield of 1.49%.

📊 Analyst Rating

3 analysts rate Lumibird (LBIRD.PA) on consensus: Strong Buy. The average price target is €29.50, implying +18.71% from the current price. Analyst price targets range from €28.50 to €30.00.

Investment Thesis: Strengths & Weaknesses

Strengths
  • High gross margin of 63.36% — indicates pricing power
  • Analyst consensus: Strong Buy
  • Positive free cash flow
Weaknesses
  • –Currently flagged as overvalued

Technical Snapshot

50-Day MA
€22.27
+11.59% vs. price
200-Day MA
€21.09
+17.83% vs. price
Below 52W High
−4.8%
€26.10
Above 52W Low
+91.2%
€13.00

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

Market Risk (Beta)
0.87 · Market-like
Moves less than the overall market
Debt-to-Equity
70.86 · Moderate
Total debt / equity

The data points to relatively defensive market behavior.

Trading Data

50-Day MA: €22.27
200-Day MA: €21.09
Volume: 51,023
Avg. Volume: 38,913
Short Ratio: —
P/B Ratio: 2.65x
Debt/Equity: 70.86x
Free Cash Flow: $3.6M

💵 Dividend Info

Dividend Yield
1.49%
Annual Rate
€0.37

Lumibird (LBIRD.PA) 2026: 23,50 EUR French Laser-and-Photonics Specialist with Scientific-Industrial-and-Medical Diversification and 1,57 Percent Dividend Yield

The Real Story

Lumibird SA (Euronext Paris: LBIRD) is a Lannion, France-headquartered laser-and-photonics-specialist designing, manufacturing, and selling various lasers for scientific, industrial, and medical applications. Three segments: Medical (ophthalmology lasers, lithotripsy), Photonics (industrial-laser-systems for marking, welding, materials-processing), and Scientific (research-grade lasers for academic-and-defense applications).

Formed 2017 from merger of Quantel and Keopsys plus subsequent acquisitions (Ellex Medical 2020). Forward-P/E 20,1x reflects expected margin-recovery.

What Smart Money Thinks

Lumibird has French-institutional base. ESIRA SAS (CEO Marc Le Flohic family-affiliated) holds approximately 20 percent. Bpifrance at approximately 8,2 percent — French sovereign-investment. Crédit Mutuel Asset Management at approximately 4,8 percent. Short-interest sits at approximately 2 percent of float as of May 2026.

Explore the BMI Smart-Money Tracker →

📈 The 3 Real Bull Points

#1 Defensive ophthalmology-laser segment provides recurring revenue base less correlated to industrial cycle

Medical-laser segment (~40 percent of revenue) provides defensive recurring base for ophthalmology procedures (cataract, refractive, retinal). Less correlated to industrial-cycle volatility.

#2 Industrial-photonics structural growth from welding, additive manufacturing, EV-battery applications

Industrial-laser demand grows approximately 8-12 percent annually from EV-battery-welding, additive-manufacturing, semiconductor-packaging applications.

#3 Le Flohic CEO 20 percent ownership plus Bpifrance 8,2 percent strategic anchor provides discipline

CEO Marc Le Flohic and Bpifrance combined 28+ percent control provides long-duration discipline through cycle.

📉 The 3 Real Bear Points

#1 Industrial laser cycle weakness compresses photonics-segment revenue

European industrial-capex weakness compresses photonics-segment revenue trajectory.

#2 Coherent, IPG Photonics, Trumpf competitive pressure compresses pricing-power

Larger laser-and-photonics competitors compress Lumibird pricing-power on industrial applications.

#3 Forward-P/E 20x is fair-value rather than deep-value — multiple-compression risk if recovery slips

Forward-P/E 20x reflects expected margin-recovery. Recovery-slip would compress multiple.

Valuation in Context

Lumibird at 23,50 EUR per share with approximately 22 million shares outstanding has a market capitalization of approximately 519 million EUR. Forward-P/E 20,1x.

Re-rating to 16-19x on consensus fiscal-2027 EPS 1,40 EUR supports 22-27 EUR — modest upside. Bear-case 14-17 EUR. Bull-case 32-38 EUR over 24-36 months.

🗓️ Next 3 Catalyst Dates

  1. 2026 Q3:

    H1 2026 earnings. Watch-items: medical-segment growth, industrial-laser cycle, margin-recovery.

  2. 2027 Q1:

    Fiscal-2026 full-year results plus fiscal-2027 guidance.

  3. 2027 H2:

    Continued industrial-cycle progression.

💬 Daniel's Take

Lumibird is a quality-cyclical French laser-and-photonics specialist with defensive ophthalmology base, industrial-photonics growth tailwind, Le Flohic-CEO and Bpifrance anchor. Position-sizing: 0,3–0,8 percent.

Sources (3)

Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.

Where can I buy Lumibird?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top
WordPress Cookie Notice by Real Cookie Banner